EMG
APLS

Ellington Management Group’s Apellis Pharmaceuticals APLS Stock Holding History

Ellington Management Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-12,600
Closed -$246K – 577
2019
Q1 		$246K Buy
+12,600
New +$198K 0.04% 418

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Ellington Management Group's APLS Position: Q2 2019 in Review

Ellington Management Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2019, closing a stake of 12,600 shares — an estimated $246K sold.

Ellington Management Group first reported a position in APLS in Q1 2019 and held it in 1 quarter. The position peaked at $246K in Q1 2019. 99 funds tracked by Wall St. Rank hold APLS as of Q2 2019.

  • Ellington Management Group reported no remaining Apellis Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Ellington Management Group sold 12,600 Apellis Pharmaceuticals shares in Q2 2019, an estimated $246K.
  • Ellington Management Group first reported a position in Apellis Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Ellington Management Group's Apellis Pharmaceuticals position peaked at $246K in Q1 2019.
  • 99 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2019.

Based on Ellington Management Group's 13F filing for Q2 2019, filed 14 Aug 2019.